DAVID POPLACK to Half-Life
This is a "connection" page, showing publications DAVID POPLACK has written about Half-Life.
Connection Strength
0.288
-
Variability in the oral bioavailability of all-trans-retinoic acid. J Natl Cancer Inst. 1993 Jun 16; 85(12):993-6.
Score: 0.027
-
Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Cancer Res. 1993 Apr 01; 53(7):1596-8.
Score: 0.026
-
Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule. Cancer Res. 1990 Aug 01; 50(15):4464-7.
Score: 0.022
-
Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates. Antimicrob Agents Chemother. 1990 Jun; 34(6):1281-4.
Score: 0.022
-
Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. J Pediatr. 1989 May; 114(5):880-4.
Score: 0.020
-
The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med. 1989 Feb 15; 110(4):279-85.
Score: 0.020
-
Preclinical pharmacology of arabinosyl-5-azacytidine in nonhuman primates. Cancer Res. 1988 Aug 01; 48(15):4294-8.
Score: 0.019
-
Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987 Feb; 5(2):202-7.
Score: 0.017
-
Folate and methotrexate polyglutamate tissue levels in rhesus monkeys following chronic low-dose methotrexate. Cancer Drug Deliv. 1987; 4(1):25-31.
Score: 0.017
-
Pharmacokinetics of 6-mercaptopurine (6MP) in the monkey. I. Disposition from plasma and cerebrospinal fluid following iv bolus. Drug Metab Dispos. 1983 Jan-Feb; 11(1):5-9.
Score: 0.013
-
Clinical pharmacology of 9-beta-D-arabinofuranosyladenine in combination with 2'-deoxycoformycin. Cancer Res. 1982 Sep; 42(9):3884-6.
Score: 0.013
-
Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1982 May; 42(5):1736-9.
Score: 0.012
-
Cerebrospinal fluid levels of 2'-deoxycoformycin after systemic administration in monkeys. J Natl Cancer Inst. 1982 Mar; 68(3):391-3.
Score: 0.012
-
L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res. 1981 Nov; 41(11 Pt 1):4554-8.
Score: 0.012
-
Experimental approaches to the treatment of CNS leukemia. Am J Pediatr Hematol Oncol. 1979; 1(2):141-9.
Score: 0.010
-
Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol. 1995 May; 13(5):1238-41.
Score: 0.008
-
Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1988 Mar; 32(3):324-6.
Score: 0.005
-
The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. Drug Metab Dispos. 1987 Sep-Oct; 15(5):595-601.
Score: 0.004
-
Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing rhesus monkeys. Cancer Treat Rep. 1982 Jun; 66(6):1333-41.
Score: 0.003
-
Misonidazole blood and cerebrospinal fluid kinetics in monkeys following intravenous and intrathecal administration. Eur J Cancer (1965). 1981 Jan; 17(1):29-34.
Score: 0.003
-
Active transport of methotrexate from cerebrospinal fluid in humans. Cancer Res. 1980 Jul; 40(7):2184-7.
Score: 0.003